Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 463 across all filing types
Latest filing 2024-03-11 Board/Management Inform…
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges regarding the appointment of a new director, Mr. Umesh Pawar, as an Additional Director and Whole-time Director of the company. It includes detailed information about the director's background, terms of appointment, and compliance with SEBI regulations. The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about changes in the company's board or management. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of announcements about changes in the company's board of directors or senior management.
2024-03-11 English
Outcome of Board Meeting
Board/Management Information Classification · 100% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding the outcome of a board meeting held on March 8, 2024. The key content is the appointment of Mr. Umesh Pawar as an Additional Director (Executive Director) of the company, subject to shareholder approval. The document includes a brief profile of the director as required by SEBI regulations. There are no financial statements, earnings data, or detailed management discussion. The document is an announcement of a board/management change, specifically the appointment of a new director. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3735 characters, which is consistent with a typical announcement rather than a full report.
2024-03-08 English
Financial Result Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement (1901 characters) addressed to stock exchanges, reporting the outcome of a board meeting held on February 13, 2024. It states that the Board of Directors approved the unaudited financial results for the quarter ended December 31, 2023, and the limited review report from the statutory auditor for the same period. The document does not contain the actual financial statements or detailed financial data but rather informs about the approval and availability of these reports on the company's and stock exchanges' websites. This fits the pattern of a Regulatory Filing (RNS) as it is a regulatory announcement about the board meeting outcome and financial results approval, not the full interim/quarterly report itself. The document is too short and does not contain substantive financial data to be classified as an Interim/Quarterly Report (IR).
2024-02-13 English
Outcome of Board Meeting
Regulatory Filings
2024-02-13 English
Board Meeting — LASA SUPERGENERICS LIMITED has informed the Exchange about Board Meeting to be held on 13-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Company fo…
Regulatory Filings
2024-02-05 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve unaudited financial results for the quarter ended December 31, 2023. It is an intimation sent to stock exchanges as per SEBI regulations. The document does not contain the financial results themselves but announces the upcoming board meeting where these results will be approved. The document length is short (1985 characters) and it is an announcement rather than a report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and meeting intimation, not an Interim Report (IR) or Earnings Release (ER).
2024-02-05 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.